Recently Featured

Three Years of Declining Overdose Deaths Sparks Cautious Optimism in Public Health

May 31, 2026
Recent data indicates a notable decline in overdose deaths over the past three years, prompting cautious optimism among public health officials and stakeholders in the pharmaceutical industry. This trend, while encouraging, surfaces a complex landscape of ongoing challenges that must be addressed to sustain progress. Factors such as the evolving nature of substance abuse, the…

Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study

May 31, 2026
Biogen reported mixed results Thursday from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets the protein tau, which is believed to contribute to cognitive decline in patients. This trial is significant as it explores an alternative to the more commonly targeted amyloid proteins, adding depth to the understanding of Alzheimer’s pathology.…

Imfinzi set to become first immunotherapy for stomach cancer patients on NHS

May 30, 2026
AstraZeneca’s Imfinzi is poised to become the first immunotherapy approved for stomach cancer patients within the National Health Service (NHS) in the UK. This landmark decision marks a significant advancement in the treatment landscape for this challenging malignancy, as Imfinzi has demonstrated the ability to extend survival rates and reduce the likelihood of cancer recurrence…

ECO 2026: Gut Hormone Signals Differ in T1D with Obesity

May 30, 2026
At the recent ECO 2026 conference, researchers unveiled significant findings regarding the fasting levels of gut hormones PYY, ghrelin, and GIP in patients with Type 1 Diabetes (T1D), particularly focusing on those with and without obesity. This study highlights a critical divergence in hormonal signaling that could influence metabolic control in T1D patients, suggesting that…

Ongoing Cases